Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
1996 1
1997 1
1998 3
1999 3
2000 4
2001 2
2002 8
2003 1
2004 3
2005 1
2006 13
2007 7
2008 13
2009 23
2010 28
2011 31
2012 37
2013 37
2014 41
2015 44
2016 58
2017 50
2018 41
2019 25
2020 33
2021 32
2022 26
2023 33
2024 30
2025 40

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

565 results

Results by year

Filters applied: . Clear all
Page 1
Silodosin.
[No authors listed] [No authors listed] 2018 Jan 8. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2018 Jan 8. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 31643499 Free Books & Documents. Review.
Silodosin is a selective alpha-1a adrenergic antagonist used in the therapy of benign prostatic hypertrophy. Silodosin is associated with a low rate of serum aminotransferase elevations and to rare instances of clinically apparent acute liver injury....
Silodosin is a selective alpha-1a adrenergic antagonist used in the therapy of benign prostatic hypertrophy. Silodosin is asso …
The effect of pelvic floor muscle training in men with benign prostatic hyperplasia and overactive bladder.
Hagovska M, Svihra J Sr, Macko L, Breza J Jr, Svihra J Jr, Luptak J, Lachvac L. Hagovska M, et al. World J Urol. 2024 May 2;42(1):287. doi: 10.1007/s00345-024-04974-7. World J Urol. 2024. PMID: 38698269 Free PMC article. Clinical Trial.
OBJECTIVE: The aim of this study was to evaluate the effect of combining pelvic floor muscle training with the urgency suppression technique (PFMT-st) and silodosin in comparison with silodosin in men with benign prostatic hyperplasia (BPH) and overactive bladder (O …
OBJECTIVE: The aim of this study was to evaluate the effect of combining pelvic floor muscle training with the urgency suppression technique …
Comparative efficacy and safety of alpha-blockers as monotherapy for benign prostatic hyperplasia: a systematic review and network meta-analysis.
Yoosuf BT, Panda AK, Kt MF, Bharti SK, Devana SK, Bansal D. Yoosuf BT, et al. Sci Rep. 2024 May 15;14(1):11116. doi: 10.1038/s41598-024-61977-5. Sci Rep. 2024. PMID: 38750153 Free PMC article.
IPSS has been considerably improved by tamsulosin 0.4 mg, naftopidil 50 mg and silodosin 8 mg as compared to the placebo. Based on the p-score, tamsulosin 0.4 mg had the highest probability of ranking for IPSS, PVR, and Qmax, whereas doxazosin 8 mg had the highest probabil …
IPSS has been considerably improved by tamsulosin 0.4 mg, naftopidil 50 mg and silodosin 8 mg as compared to the placebo. Based on th …
Promising selective alpha-1 blocker silodosin as a new therapeutic strategy for premature ejaculation and analysis of its drug adverse effect: A systematic review and meta-analysis of randomized controlled trials.
Fauzan MI, Daryanto B, Budaya TN, Makkaraka MAG, Fakhri M, Rahman IA. Fauzan MI, et al. Arch Ital Urol Androl. 2024 Nov 11;96(4):12984. doi: 10.4081/aiua.2024.12984. Arch Ital Urol Androl. 2024. PMID: 39692416 Free article.
CONCLUSIONS: Silodosin significantly increased IELT. However, it also reduced semen ejaculation as its drug adverse effect. This result supports the clinical use of silodosin as an alternative treatment for premature ejaculation....
CONCLUSIONS: Silodosin significantly increased IELT. However, it also reduced semen ejaculation as its drug adverse effect. This resu …
Silodosin for benign prostatic hyperplasia.
Cantrell MA, Bream-Rouwenhorst HR, Hemerson P, Magera JS Jr. Cantrell MA, et al. Ann Pharmacother. 2010 Feb;44(2):302-10. doi: 10.1345/aph.1M320. Epub 2010 Jan 13. Ann Pharmacother. 2010. PMID: 20071497 Review.
OBJECTIVE: To review the pharmacology, pharmacokinetics, clinical trials, and safety of silodosin, a recently approved alpha(1A)-adrenergic receptor (AR) antagonist for benign prostatic hyperplasia (BPH). ...The usual dose of silodosin is 8 mg once daily and should …
OBJECTIVE: To review the pharmacology, pharmacokinetics, clinical trials, and safety of silodosin, a recently approved alpha(1A)-adre …
Does Silodosin Improve Primary Ureteroscopy Access and Outcomes: Meta-Analysis of Randomized Controlled Trials.
Adhoni MZU, Haider M, Somani B, Ali Z. Adhoni MZU, et al. J Endourol. 2024 Nov;38(11):1148-1155. doi: 10.1089/end.2024.0413. Epub 2024 Sep 16. J Endourol. 2024. PMID: 39180290

Results: Eight RCTs with a total of 892 patients (416 in the silodosin group and 476 in the control group) met the inclusion criteria. Silodosin significantly reduced operative time by 15.74 minutes (p < 0.00001). The access rate was higher in the silodosin

…
Results: Eight RCTs with a total of 892 patients (416 in the silodosin group and 476 in the control group) met the inclusion criteria …
Role of silodosin as medical expulsive therapy in ureteral calculi: a meta-analysis of randomized controlled trials.
Liu XJ, Wen JG, Wan YD, Hu BW, Wang QW, Wang Y. Liu XJ, et al. Urolithiasis. 2018 Apr;46(2):211-218. doi: 10.1007/s00240-017-0974-1. Epub 2017 Apr 1. Urolithiasis. 2018. PMID: 28365782
The objective of this study is to investigate the efficacy of silodosin in medical expulsive therapy (MET) for ureteral stones. We conducted a systematic review and meta-analysis to determine the efficacy and safety of silodosin in MET for ureteral calculi. ...Si …
The objective of this study is to investigate the efficacy of silodosin in medical expulsive therapy (MET) for ureteral stones. We co …
Systematic review and meta-analysis of randomized controlled trials evaluating silodosin in the treatment of non-neurogenic male lower urinary tract symptoms suggestive of benign prostatic enlargement.
Novara G, Tubaro A, Sanseverino R, Spatafora S, Artibani W, Zattoni F, Montorsi F, Chapple CR. Novara G, et al. World J Urol. 2013 Aug;31(4):997-1008. doi: 10.1007/s00345-012-0944-8. Epub 2012 Sep 28. World J Urol. 2013. PMID: 23053207
Silodosin was more effective than tamsulosin 0.2 mg with regard to some IPSS-related parameters. ...With regard to adverse events, AEj was more common with silodosin. All the adverse events other than AEj were significantly more common with tamsulosin 0.2 and 0.4 mg …
Silodosin was more effective than tamsulosin 0.2 mg with regard to some IPSS-related parameters. ...With regard to adverse events, AE …
Silodosin for benign prostatic hypertrophy.
[No authors listed] [No authors listed] Aust Prescr. 2018 Aug;41(4):129-130. doi: 10.18773/austprescr.2018.030. Epub 2018 Jun 12. Aust Prescr. 2018. PMID: 30116085 Free PMC article. Review. No abstract available.
565 results